Multivariate time-dependent Cox model for OS
| . | HR (95% CI) . | P . |
|---|---|---|
| All patients (n = 318) | ||
| 2017 ELN intermediate-risk group* | 1.75 (1.11-2.76) | .017 |
| 2017 ELN adverse-risk group* | 2.64 (1.69-4.13) | <.001 |
| Allogeneic HCT | 0.57 (0.42-0.94) | .021 |
| Age | 1.01 (0.99-1.02) | .709 |
| WBC count (log10) | 1.51 (1.11-2.00) | .009 |
| Female vs male | 0.77 (0.54-0.99) | .045 |
| Treatment (midostaurin vs placebo) | 0.55 (0.43-0.83) | <.002 |
| BM blasts (log2) | 1.03 (0.84-1.37) | .603 |
| Favorable-risk group (n = 85) | ||
| Allogeneic HCT | 0.78 (0.28-2.13) | .621 |
| Age | 1.02 (0.97-1.06) | .515 |
| WBC count (log10) | 0.89 (0.44-1.82) | .750 |
| Female vs male | 0.53 (0.24-1.14) | .102 |
| Treatment (midostaurin vs placebo) | 0.48 (0.20-1.11) | .086 |
| BM blasts (log2) | 0.98 (0.62-1.54) | .916 |
| Intermediate-risk group (n = 111) | ||
| Allogeneic HCT | 0.81 (0.41-1.58) | .535 |
| Age | 1.02 (0.99-1.05) | .178 |
| WBC count (log10) | 2.03 (1.16-3.55) | .013 |
| Female vs male | 1.06 (0.61-1.82) | .846 |
| Treatment (midostaurin vs placebo) | 0.53 (0.31-0.89) | .018 |
| BM blasts (log2) | 1.17 (0.68-2.01) | .761 |
| Adverse-risk group (n = 122) | ||
| Allogeneic HCT | 0.39 (0.21-0.73) | .003 |
| Age | 1.00 (0.98-1.02) | .867 |
| WBC count (log10) | 1.52 (0.97-2.38) | .068 |
| Female vs male | 0.66 (0.42-1.06) | .085 |
| Treatment (midostaurin vs placebo) | 0.51 (0.31-0.82) | .006 |
| BM blasts (log2) | 0.98 (0.65-1.48) | .928 |
| . | HR (95% CI) . | P . |
|---|---|---|
| All patients (n = 318) | ||
| 2017 ELN intermediate-risk group* | 1.75 (1.11-2.76) | .017 |
| 2017 ELN adverse-risk group* | 2.64 (1.69-4.13) | <.001 |
| Allogeneic HCT | 0.57 (0.42-0.94) | .021 |
| Age | 1.01 (0.99-1.02) | .709 |
| WBC count (log10) | 1.51 (1.11-2.00) | .009 |
| Female vs male | 0.77 (0.54-0.99) | .045 |
| Treatment (midostaurin vs placebo) | 0.55 (0.43-0.83) | <.002 |
| BM blasts (log2) | 1.03 (0.84-1.37) | .603 |
| Favorable-risk group (n = 85) | ||
| Allogeneic HCT | 0.78 (0.28-2.13) | .621 |
| Age | 1.02 (0.97-1.06) | .515 |
| WBC count (log10) | 0.89 (0.44-1.82) | .750 |
| Female vs male | 0.53 (0.24-1.14) | .102 |
| Treatment (midostaurin vs placebo) | 0.48 (0.20-1.11) | .086 |
| BM blasts (log2) | 0.98 (0.62-1.54) | .916 |
| Intermediate-risk group (n = 111) | ||
| Allogeneic HCT | 0.81 (0.41-1.58) | .535 |
| Age | 1.02 (0.99-1.05) | .178 |
| WBC count (log10) | 2.03 (1.16-3.55) | .013 |
| Female vs male | 1.06 (0.61-1.82) | .846 |
| Treatment (midostaurin vs placebo) | 0.53 (0.31-0.89) | .018 |
| BM blasts (log2) | 1.17 (0.68-2.01) | .761 |
| Adverse-risk group (n = 122) | ||
| Allogeneic HCT | 0.39 (0.21-0.73) | .003 |
| Age | 1.00 (0.98-1.02) | .867 |
| WBC count (log10) | 1.52 (0.97-2.38) | .068 |
| Female vs male | 0.66 (0.42-1.06) | .085 |
| Treatment (midostaurin vs placebo) | 0.51 (0.31-0.82) | .006 |
| BM blasts (log2) | 0.98 (0.65-1.48) | .928 |
Favorable-risk group was used as reference.